As there is no specific therapy for PLN-R14del-related cardiomyopathy, current HF guidelines, which recommend treatment with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and MRAs or a combination, are applied for treatment12. This evidence concerns the gene ACE and hydrops fetalis.